Language
English
Publication Date
1-1-2024
Journal
WIREs Nanomedicine and Nanobiotechnology
DOI
10.1002/wnan.1946
PMID
38426638
PMCID
PMC10983770
PubMedCentral® Posted Date
3-1-2025
PubMedCentral® Full Text Version
Author MSS
Abstract
Alzheimer's disease is the most common cause of dementia and a leading cause of mortality in the elderly population. Diagnosis of Alzheimer's disease has traditionally relied on evaluation of clinical symptoms for cognitive impairment with a definitive diagnosis requiring post-mortem demonstration of neuropathology. However, advances in disease pathogenesis have revealed that patients exhibit Alzheimer's disease pathology several decades before the manifestation of clinical symptoms. Magnetic resonance imaging (MRI) plays an important role in the management of patients with Alzheimer's disease. The clinical availability of molecular MRI (mMRI) contrast agents can revolutionize the diagnosis of Alzheimer's disease. In this article, we review advances in nanoparticle contrast agents, also referred to as nanoprobes, for mMRI of Alzheimer's disease. This article is categorized under: Diagnostic Tools > In Vivo Nanodiagnostics and Imaging Therapeutic Approaches and Drug Discovery > Nanomedicine for Neurological Disease.
Keywords
Humans, Aged, Alzheimer Disease, Contrast Media, Positron-Emission Tomography, Cognitive Dysfunction, Magnetic Resonance Imaging, Brain, molecular imaging, magnetic resonance imaging, nanoprobes, nanoparticle contrast agent, Alzheimer’s disease, amyloid, tau, neuron, microglia, neuroinflammation, neurodegeneration
Published Open-Access
yes
Recommended Citation
Parekh, Parag; Badachhape, Andrew A; Tanifum, Eric A; et al., "Advances in Nanoprobes for Molecular MRI of Alzheimer’s Disease" (2024). Faculty, Staff and Students Publications. 6428.
https://digitalcommons.library.tmc.edu/baylor_docs/6428
Graphical Abstract